Lineage Cell Therapeutics (LCTX) Expected to Release Quarterly Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is projected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Lineage Cell Therapeutics to post earnings of ($0.02) per share and revenue of $2.32 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its earnings results on Thursday, August 6th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). Lineage Cell Therapeutics had a negative net margin of 246.58% and a negative return on equity of 73.06%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.84 million. On average, analysts expect Lineage Cell Therapeutics to post ($0.07) EPS for the current fiscal year and ($0.04) EPS for the next fiscal year.

Lineage Cell Therapeutics Price Performance

LCTX opened at $1.01 on Wednesday. The company’s 50-day moving average is $1.01 and its 200 day moving average is $1.32. Lineage Cell Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $1.99.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Tuesday, July 14th. Four analysts have rated the stock with a Buy rating. According to MarketBeat.com, Lineage Cell Therapeutics presently has a consensus rating of “Buy” and an average price target of $6.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company uses its proprietary cell differentiation and manufacturing technologies to create specialized human cells intended to replace, repair or support damaged tissues.

Lineage’s lead program, OpRegen, is an investigational retinal pigment epithelium cell replacement therapy being developed for geographic atrophy, an advanced form of dry age-related macular degeneration.